AIXIAL GROUP

About AIXIAL GROUP

Cmed Group, established in 2000 by Dr. David Connelly, operates as a technology-focused contract research organization (CRO). Dr. Connelly, who holds a PhD in Pharmacology, leveraged over two decades of experience in the pharmaceutical and CRO industries to found and lead the company's growth into a multinational full-service CRO. His expertise spans clinical trial design, operations, biostatistics, and data management. In May 2021, Cmed was acquired by Aixial Group, the CRO division of the French engineering and technology consultant, Alten Group. This acquisition was a strategic move to expand Aixial's geographical coverage and enhance its service offerings, creating a combined entity with over 1,000 employees across the US and Europe.

The company's business model is centered on providing comprehensive clinical trial services and technology solutions to a global client base of biopharmaceutical and medical device partners. Cmed specializes in complex therapeutic areas, particularly oncology, immuno-oncology, cell therapy, and rare diseases. Its revenue is generated by delivering a suite of services that includes clinical operations, data sciences and analytics, regulatory affairs, and product development support. The firm has a track record of managing early-phase (I to IIb) clinical trials effectively, along with an increasing number of Phase III studies.

A key differentiator for Cmed is its proprietary clinical data suite, Encapsia. This enterprise cloud-based platform is designed to support a full range of clinical trials, including traditional, decentralized, virtual, and hybrid models. Encapsia provides a unified solution for collecting, managing, and reporting clinical data from multiple sources in real-time. Its features include electronic data capture (EDC) via web or mobile apps, eSource for direct data entry, and a Home Visit app to manage data capture from patients' homes. The platform is built to streamline trial processes, offering sophisticated data visualizations, analytics, and AI capabilities to help clients reduce costs and accelerate drug development timelines.